Next Science (ASX:NXS) Change In Receivables : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Next Science Change In Receivables?

Next Science's change in receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Next Science's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Next Science's change in receivables for the fiscal year that ended in Dec. 2023 was A$0.00 Mil. It means Next Science's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Next Science's Accounts Receivable for the quarter that ended in Dec. 2023 was A$5.17 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Next Science's Days Sales Outstanding for the six months ended in Dec. 2023 was 52.35.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Next Science's liquidation value for the six months ended in Dec. 2023 was A$10.69 Mil.

Next Science Change In Receivables Historical Data

The historical data trend for Next Science's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Change In Receivables Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial					-	-	-	-	-

Next Science Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Next Science (ASX:NXS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Next Science's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	5.171	/	18.028	*	91
=	52.35

2. In Ben Graham's calculation of liquidation value, Next Science's accounts receivable are only considered to be worth 75% of book value:

Next Science's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	13.86	-	7.588	+	0.75 * 5.171	+	0.5 * 1.077
=	10.69

Next Science Change In Receivables Related Terms

Thank you for viewing the detailed overview of Next Science's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (ASX:NXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines